Literature DB >> 16766229

Engineering mucosal RNA interference in vivo.

Yingjie Zhang1, Patricia Cristofaro, Rebecca Silbermann, Oliver Pusch, Daniel Boden, Tamako Konkin, Virginia Hovanesian, Paul R Monfils, Murray Resnick, Steven F Moss, Bharat Ramratnam.   

Abstract

Mucosal surfaces serve as a gateway to disease. Here, we demonstrate that RNA interference can be used to manipulate mucosal gene expression in vivo. Using a murine model, we show that direct application of liposome-complexed siRNA mediates gene-specific silencing in cervicovaginal and rectal mucosa. A single vaginal or rectal administration of siRNA targeting hematopoietic or somatic cell gene products reduced corresponding mRNA levels by up to 90%. Using a murine model of inflammatory bowel disease, we found that the rectal application of siRNA targeting TNF-alpha led to relative mucosal resistance to experimental colitis. Liposomal siRNA formulations proved nontoxic, did not elicit a nonspecific interferon response, and provide a means for genetic engineering of mucosal surfaces in vivo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16766229     DOI: 10.1016/j.ymthe.2006.04.001

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  37 in total

Review 1.  Shielding the messenger (RNA): microRNA-based anticancer therapies.

Authors:  Elena Sotillo; Andrei Thomas-Tikhonenko
Journal:  Pharmacol Ther       Date:  2011-04-14       Impact factor: 12.310

2.  Functionally enhanced siRNA targeting TNFα attenuates DSS-induced colitis and TLR-mediated immunostimulation in mice.

Authors:  Sandra M Ocampo; Carolina Romero; Anna Aviñó; Joan Burgueño; Miguel A Gassull; Jordi Bermúdez; Ramon Eritja; Ester Fernandez; Jose C Perales
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

Review 3.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

Review 4.  Lipidic systems for in vivo siRNA delivery.

Authors:  Sherry Y Wu; Nigel A J McMillan
Journal:  AAPS J       Date:  2009-09-09       Impact factor: 4.009

Review 5.  Optimizing siRNA delivery to the genital mucosa.

Authors:  Joseph A Katakowski; Deborah Palliser
Journal:  Discov Med       Date:  2011-02       Impact factor: 2.970

6.  Mouse and human Notch-1 regulate mucosal immune responses.

Authors:  D R Mathern; L E Laitman; Z Hovhannisyan; D Dunkin; S Farsio; T J Malik; G Roda; A Chitre; A C Iuga; G Yeretssian; M C Berin; S Dahan
Journal:  Mucosal Immunol       Date:  2014-01-15       Impact factor: 7.313

7.  The application of RNAi-based treatments for inflammatory bowel disease.

Authors:  Morten Tobias Jarlstad Olesen; Borja Ballarín-González; Kenneth Alan Howard
Journal:  Drug Deliv Transl Res       Date:  2014-02       Impact factor: 4.617

8.  FODMAP diet modulates visceral nociception by lipopolysaccharide-mediated intestinal inflammation and barrier dysfunction.

Authors:  Shi-Yi Zhou; Merritt Gillilland; Xiaoyin Wu; Pornchai Leelasinjaroen; Guanpo Zhang; Hui Zhou; Bo Ye; Yuanxu Lu; Chung Owyang
Journal:  J Clin Invest       Date:  2017-11-27       Impact factor: 14.808

9.  Aptamer-targeted cell-specific RNA interference.

Authors:  Jiehua Zhou; John J Rossi
Journal:  Silence       Date:  2010-02-01

10.  Ubiquitin-editing enzyme A20 promotes tolerance to lipopolysaccharide in enterocytes.

Authors:  Jin Wang; Yannan Ouyang; Yigit Guner; Henri R Ford; Anatoly V Grishin
Journal:  J Immunol       Date:  2009-07-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.